Onternabez

Onternabez
Clinical data
Other names	HU-308, HU308, PPP-003, ARDS-003
Drug class	CB2 receptor agonist
ATC code	None;
Legal status
Legal status	CA: Schedule II; UK: Class B; US: Unscheduled ; ; Florida: Schedule I;
Pharmacokinetic data
Metabolism	Liver
Excretion	Kidneys
Identifiers
	IUPAC name [(1S,2S,5S)-2-[2,6-Dimethoxy-4-(2-methyloctan-2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]methanol;
CAS Number	256934-39-1 ;
PubChem CID	11553430;
ChemSpider	8020425;
UNII	8I5L034D55;
KEGG	D12305;
ChEBI	CHEBI:146244;
CompTox Dashboard (EPA)	DTXSID801017327 ;
Chemical and physical data
Formula	C27H42O3
Molar mass	414.630 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCCCC(C)(C)C1=CC(=C(C(=C1)OC)[C@H]2C=C([C@@H]3C[C@H]2C3(C)C)CO)OC;
	InChI InChI=1S/C27H42O3/c1-8-9-10-11-12-26(2,3)19-14-23(29-6)25(24(15-19)30-7)20-13-18(17-28)21-16-22(20)27(21,4)5/h13-15,20-22,28H,8-12,16-17H2,1-7H3/t20-,21-,22+/m0/s1; Key:CFMRIVODIXTERW-FDFHNCONSA-N;
	(what is this?) (verify)

Onternabez (also known as HU-308, HU308, PPP-003, and ARDS-003) is a synthetic cannabinoid that acts as a potent cannabinoid agonist. It is highly selective for the cannabinoid-2 receptor (CB₂ receptor) subtype, with a selectivity more than 5,000 times greater for the CB₂ receptor than the CB₁ receptor. The synthesis and characterization of onternabez took place in the laboratory of Raphael Mechoulam at the Hebrew University of Jerusalem (the HU in HU-308) in the late 1990s. The pinene dimethoxy-DMH-CBD derivative onternabez was identified as a potent peripheral CB₂-selective agonist in in vitro and animal studies in 1990 and 1999.